Kowal Investment Group LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Kowal Investment Group LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 7.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,475 shares of the biopharmaceutical company’s stock after selling 1,359 shares during the period. Kowal Investment Group LLC’s holdings in Pfizer were worth $506,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Olistico Wealth LLC purchased a new stake in Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter valued at about $29,000. Quarry LP acquired a new stake in Pfizer during the second quarter worth about $31,000. Trivant Custom Portfolio Group LLC raised its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the 2nd quarter valued at about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.7 %

PFE opened at $29.66 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $168.07 billion, a price-to-earnings ratio of -494.33, a PEG ratio of 1.30 and a beta of 0.67. The business has a fifty day moving average price of $29.04 and a 200 day moving average price of $28.42. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.19.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.67 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.66%. Pfizer’s payout ratio is currently -2,800.00%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.